RNS Number:5217M
Cobra Bio-Manufacturing PLC
25 January 2008



For Immediate Release                                            25 January 2008


                          Cobra Biomanufacturing Plc

                    COBRA ANNOUNCES MANUFACTURING AGREEMENT
                                 FOR TNFERADE(TM) 


Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer
of biopharmaceuticals, today announces that it has entered into a manufacturing
development agreement with GenVec, Inc. for TNFerade(TM), GenVec's lead product
candidate. The agreement will cover technology transfer, scale-up, and
validation of the manufacturing process for TNFerade through cGMP consistency
lots that will be produced at Cobra's facility in Oxford, United Kingdom.

"GenVec selected Cobra based upon their expertise in viral manufacturing and the
experience of key staff members with commercial biopharmaceutical products.
Activities under this agreement will establish a clear path for the submission
of the chemistry, manufacturing, and controls (CMC) portion of a biological
license application for TNFerade as GenVec works towards the completion of our
current Phase III clinical trial," said Dr. Bryan Butman, GenVec's Senior Vice
President of Vector Operations.

"We are delighted to work with GenVec on this exciting project. TNFerade has
demonstrated great potential for the treatment of pancreatic cancer," added
Simon Saxby, Cobra Biomanufacturing's Chief Operating Officer. "This agreement
will leverage Cobra's significant experience manufacturing recombinant
adenovirus under cGMP conditions."


About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs
and vaccines. GenVec's lead product, TNFerade(TM) is currently in a pivotal
clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical
trials are in progress in rectal cancer, head and neck cancer and melanoma.
GenVec also uses its proprietary adenovector technology to develop vaccines for
infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory
syncytial virus (RSV), and influenza. Additional information about GenVec is
available at www.genvec.com and in the company's various filings with the
Securities and Exchange Commission.


About TNFerade(TM)

TNFerade is an adenovector, or DNA carrier, which contains the gene for tumor
necrosis factor-alpha (TNF alpha), an immune system protein with potent and
well-documented anti-cancer effects, for direct injection into tumors. After
administration, TNFerade stimulates the production of TNF alpha in the tumor.
GenVec is developing TNFerade for use in combination with radiation and/or
chemotherapy for the treatment of various cancers.



                                    - ENDS -



For further information, please contact:


Cobra Biomanufacturing Plc                             Tel: +44 (0) 1782 714 181
Simon Saxby, Chief Operating Officer

Buchanan Communications                                Tel: +44 (0) 207 466 5000
Tim Anderson/Rebecca Skye Dietrich

College Hill Life Sciences                             Tel: +44 (0) 20 7457 2020
Gemma Price

Seymour Pierce (NOMAD & Broker)                        Tel: +44 (0) 20 107 8000
Stuart Lane



Notes to Editors:

About Cobra Biomanufacturing Plc:

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products.

Cobra has developed a range of unique, patented technologies, which underpin a
successful revenue generating contract manufacturing business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising �7 million and raised a further �5.2 million in May 2003 in
order to further expand capacity in Oxford UK. Since floatation the Company has
grown turnover from $6m to $20m providing expert manufacturing services across
the world with over 80% of revenues currently originating from the US market.

www.cobrabio.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRFKQKPOBKDBDB
Cobra Bio-manufacturing (LSE:CBF)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Cobra Bio-manufacturing Charts.
Cobra Bio-manufacturing (LSE:CBF)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Cobra Bio-manufacturing Charts.